Life Tech Sublicenses TALENS Technology to ToolGen, CDI | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today announced the launch of a sublicensing program for technology covering nucleic acids encoding Transcription Activator-Like Effector Nuclease fusion proteins, or TALENS, one month after a patent for the technology was issued.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

Widespread genome sequencing might not be justified just yet, USA Today reports.